You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Precision Quality Check of Immunotherapeutics via Single Cell Cytokine Mapping
SBC: ISOPLEXIS CORPORATION Topic: 102Despite the demonstrated benefit of CD targeted CAR T immunotherapeutics two challenges remain to bringing the therapeutics to market The first key challenge is to reproducibly manufacture the therapy so that the cellsandapos cytokine mediated function acts in a predictably consistent fashion post manufacturing The second key challenge is to manage the cellandapos s adverse effect immuno to ...
SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Development of a rapid and inexpensive luciferase-based high throughput screening assay to identify compounds that alter pancreatic β cell function
SBC: Regenerative Medical Solutions Inc Topic: 200Project Summary Abstract The prevalence of diabetes in the United States and world wide is increasing dramatically and new drugs that can protect or restore the function of insulin producing pancreatic beta cells are urgently needed For decades diabetes drug discovery efforts have been hampered by two things the lack of abundant human beta cells for drug screening and the difficultly an ...
SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Engineered pancreatic endocrine cells that report beta cell toxicity for use in high throughput screening applications
SBC: Regenerative Medical Solutions Inc Topic: 200Project Summary Abstract The prevalence of diabetes in the United States and world wide is increasing dramatically and new drugs that can protect or restore the function of insulin producing pancreatic beta cells are urgently needed For decades drug discovery efforts in this space have been hampered by the lack of consistent and abundant human beta cells for drug screening The advent of beta c ...
SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
A mobile app to reduce treatment-related financial burden for cancer patients
SBC: Vivor, Llc Topic: NCIThere is a fundamental knowledge gap in how to immediately reduce cancer patientsandapos treatment related financial burden Cancer patients pay more out of pocket for their care than those with other chronic illnesses Half of all elderly cancer patients have high treatment related out of pocket financial burden This financial burden has well defined harmful effects even among insured cancer pa ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
An Ultra filtrate perfusion bio artificial pancreas for high-density islet replacement without immunosuppression
SBC: Norfolk Medical Products, INC. Topic: NIDDKDESCRIPTION provided by applicant The Cell SafeTM is a fundamentally new approach in replacement of dysfunctional insulin producing cells in patients with diabetes by transplantation of new islets in a three dimensional scaffold embedded in a highly compatible bioengineered perfusion system that continuously supplies tissue fluid blood ultrafiltrate so that the cells ae protected from immun ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
A Novel Pharmacological Treatment for Neuropathic Pain
SBC: Aptinyx Inc Topic: 105PROJECT SUMMARY Neuropathic pain NP conditions affect up to of the population while the annual costs of treatment reach $ billion in the US Pain reduction is more difficult to achieve in NP since the mechanisms involved are not the same as the mechanisms of normal nociceptive pain Current therapeutic approaches offer limited pain relief and frequently produce side effects that outweig ...
SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Better Living After Stroke through Technology BLAST
SBC: BRIGHTOUTCOME INC. Topic: 600DESCRIPTION provided by applicant Stroke the leading cause of disability cognitive impairment and death in the US imposes significant financial and personal burden The residual effects of stroke affect many aspects of life not addressed by traditional rehabilitation treatments In particular persons with mild stroke typically defined as a stroke with no or sligh motor impairment and a high ...
SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Real-time volumetric specimen imager for 3D intra-operative lumpectomy margin assessment
SBC: CLARIX IMAGING CORP Topic: 102DESCRIPTION provided by applicant We propose to develop a novel volumetric specimen imager VSI device for significantly reducing breast lumpectomyandapos s reoperation rate and improving outcomes Among the annual performance of andgt lumpectomies in the US up to of patients need a reoperation when post surgery pathology examination reveals andquot positive marginandquot ...
SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
A Proton Radiography System for Optimization of Proton Therapy
SBC: ProtonVDA LLC Topic: 102Proton radiography produces images of patients in terms of proton stopping power by tracking individual protons before and after the patient and measuring the proton residual range after traversing the patient and would be the most direct method of image guidance for proton radiation therapy Radiation therapy is needed for more than of the million Americans who are annually diagnosed wi ...
SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Buccal Nanocytological Risk Stratification to Personalize Lung Cancer Screening
SBC: NANOCYTOMICS LLC Topic: 102Project Summary Abstract This goal of this SBIR project is to develop a commercial grade Nanocytology system for FDA clinical trials and subsequent commercialization of a lung cancer risk stratification test to personalize lung cancer screening Lung cancer is the leading cause of cancer deaths in the U S The reason for the lethality of lung cancer relates to its tendency to be diagnosed at a lat ...
SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health